Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b, Double-Blind, Multicenter, Randomized Study to Compare the Efficacy and Safety of Single Dose Dalbavancin to a Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

NCT02127970 is registered in ClinicalTrials.gov with Durata Therapeutics Inc., an affiliate of Allergan plc as lead sponsor.

NCT NCT02127970
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02127970 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b, Double-Blind, Multicenter, Randomized Study to Compare the Efficacy and Safety of Single Dose Dalbavancin to a Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Lead sponsor
Durata Therapeutics Inc., an affiliate of Allergan plc
Phase
Phase 3
Overall status
Completed
Start date
April 18, 2014
Completion date
March 11, 2015
Enrollment
698 (actual)
Sites
78

Conditions

As the registry lists them; a condition with its own page is linked.

abscess, cellulitis, surgical site infection, wound infection